Key focuses will be to keep the number of uninsured Americans low and avoid disadvantaging people with difficult conditions, he said.
Gorsky added that Trump’s criticism of the pharmaceutical industry and drug prices, is “much broader than just a pharmaceutical issue.”
“Health care or pharmaceuticals only represent about 10 to 15 percent of overall health care spend,” he said.
Meanwhile, he said, many of the improvements to life expectancy are due to new treatment drugs.
“What’s important is to make sure, obviously, that (pharmaceuticals companies) continue to innovate…that we price responsibly and that we work on some of the reimbursement mechanisms, be it Medicare, Medicaid or through private insurance,” he said.